NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FI, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, AL, AD, AM, AZ, BY, BA, GE, IS, KZ, LI, MD, MC, ME, MK, NO, RU, SM, RS, CH, TR, UA, VA”]
Marianne Brodmann (Medical University of Graz, Division of Angiology, Austria) talks about the clinical results of the EMINENT randomised controlled trial, arguing that drug-eluting stents (DES) will be the standard of care in treating superficial femoral artery (SFA) femoropopliteal lesions. Brodmann discusses what drives her decision when choosing either a DES or drug-coated balloon.
This video was filmed by Boston Scientific and is being sponsored for distribution in association with Vascular News. Biba Medical bears no responsibility for the assets used in the production of this video.
View the clinical trial results
Evidence in the SFA: Best strategy for treatment of the femoropopliteal segment
Evidence in the SFA: What kind of stent should we use?
Evidence in the SFA: Considering the data when making decisions for patients
[/geoip-content]
